Heska NuQ Cancer Screening Test

Nu.Q®

Discover the risk for certain canine cancers in-house, instantly.

Nu.Q® on the Element i+ analyzer is exclusively available from Antech as an in-house test option.

  • Accurate & Convenient

    Only requires 50μL of EDTA plasma from a patient with high (>70%) detection rates for lymphoma and hemangiosarcoma -all at an affordable cost for pet owners.

  • Exclusively In-House with Antech

    Evaluate risk of certain cancer types instantly, right at your fingertips. Simply run a Nu.Q® blood test on the in-house Element i+ analyzer.

  • Seamless Integration

    The efficient workflow for Nu.Q® on the Element i+ analyzer makes it easy to add to routine wellness diagnostics for your patients that are at high risk for cancer.

  • Cutting Edge

    Element i+ delivers fast and accurate immunodiagnostic test results on a sleek and compact platform with an expanding test menu.

  • Innovative Cancer Assessment

    Measures canine plasma nucleosome concentration and helps determine current likelihood of certain cancers.

  • Affordable Testing & Immediate Results

    Refine your differential list in minutes, helping you inform pet owners of risk level for common cancer types.

Stop overpaying for in-clinic blood testing and analysis.

Heska’s Reset program provides veterinarians with accurate, better and faster blood testing and analysis up to 40% less cost than with other competitive in-house diagnostic laboratory services.

Learn More

Nu.Q® on the Element i+ is the industry's only in-house canine cancer blood test, offered exclusively by Antech.

Evaluate risk of certain cancer types instantly.

Innovative

Measures canine plasma nucleosome concentration and helps determine current likelihood of certain cancers.

Accurate, Fast and In-House

Get quantitative results and develop a plan of action before your patient goes home.

Convenient

Requiring only 50 uL of EDTA plasma from your patient.

Technical Details & Downloads

Empowering veterinary care teams with the industry’s only in-house canine cancer blood test.

1 in 4 dogs get cancer.1  Cancer is a leading cause of death in older dogs, with nearly 50% over 10 years of age developing the disease. Over 6 million dogs are diagnosedwith cancer in the United States every year — often far too late. With Nu.Q®, you can help determine the current likelihood of certain cancers — like lymphoma and hemangiosarcoma. Nu.Q® on the Element i+ allows you to interpret results and develop a plan of action before your patient goes home.

Indications:

  • Older dogs (≥7 years of age)
  • Younger dog breeds (≥4 years of age) known to be at a higher risk of developing cancer 

Element i+ delivers fast and accurate immunodiagnostic test results on a sleek and compact platform with an expanding test menu. You can evaluate risk of certain cancer types instantly, right at your fingertips. Simply run a Nu.Q® blood test on the in-house Element i+ analyzer — both cost-effective and simple, requiring only 50μL of EDTA plasma from your patient. Nu.Q® is an accessible, affordable, and quantitative blood test for nucleosomes in dogs.

The Element i+ Immunodiagnostic Analyzer supports your diagnostic needs with the following tests:
Canine Cancer | T4 | cTSH | Cortisol | Progesterone | cCRP

All on a sleek and compact platform offering…

  • Accurate and fast quantitative results
  • Touch screen for easy operation
  • Room temperature storage of test cartridges
  • Bi-directional interface simplifies patient data entry with PMS integration

 

REFERENCES:

1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from https://www.avma.org/resources/pet-owners/petcare/cancer-pets

2. National Cancer Institute: https://ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-onc#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year

3. Wilson-Robles, H., Bygott, T., Kelly, T., Miller, T., Miller, P., & Matsushita, M. et al. (2022). Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research, 18(1). https://doi.org/10.1186/s12917-022-03429-8

PEER-REVIEWED STUDIES

Lymphoma paper: https://pubmed.ncbi.nlm.nih.gov/34399763/

Hemangiosarcoma paper: https://pubmed.ncbi.nlm.nih.gov/34187493/

2020 cancer vs healthy dogs: https://pubmed.ncbi.nlm.nih.gov/32866177/

*Nu.Q® ️is not a confirmatory test for cancer. Nu.Q®️ results should act as an impetus to perform additional diagnostics to obtain a diagnosis. Elevated plasma nucleosome concentration does not tell you which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.

Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied to Antech’s Heska affiliate under license by Belgian Volition SRL.

The Element i+ analyzer uses cutting-edge immunodiagnostics technology.

How does Nu.Q® work?

  • DNA is compacted within a cell’s nucleus in the form of chromosomes.
  • Nucleosomes (small, structural units comprised of DNA and a histone protein core) allow chromosomes to stack and fold into their normal conformation within each cell nucleus.
  • For certain types of cancer, nucleosomes are released into the blood and can be measured using specific antibodies.
  • Nucleosomes in patient plasma measured with Nu.Q® can serve as a biomarker to help identify patients who may have cancer.3

 

 

 

 

REFERENCES:

1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from https://www.avma.org/resources/pet-owners/petcare/cancer-pets

2. National Cancer Institute: https://ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-onc#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year

3. Wilson-Robles, H., Bygott, T., Kelly, T., Miller, T., Miller, P., & Matsushita, M. et al. (2022). Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research, 18(1). https://doi.org/10.1186/s12917-022-03429-8

PEER-REVIEWED STUDIES

Lymphoma paper: https://pubmed.ncbi.nlm.nih.gov/34399763/

Hemangiosarcoma paper: https://pubmed.ncbi.nlm.nih.gov/34187493/

2020 cancer vs healthy dogs: https://pubmed.ncbi.nlm.nih.gov/32866177/

*Nu.Q® ️is not a confirmatory test for cancer. Nu.Q®️ results should act as an impetus to perform additional diagnostics to obtain a diagnosis. Elevated plasma nucleosome concentration does not tell you which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.

Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied to Antech’s Heska affiliate under license by Belgian Volition SRL.

Heska Support Teams are Here for You

We’re Available When You Need Us

Rest assured that when you need help, have questions, or have difficulties, we have you covered.